Nathan P. S.
- Country
- France
- Department
- Maladies Infectieuses et tropicales
Research Overview
- OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Study
- Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct)
- European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct)
Data & Insights
Has run more than one trial at 79 of 226 partner sites.
Specializations
Viral Infections
Specializes in treating COVID-19 in diverse patient populations, with particular focus on immunocompromised patients. Investigates novel antiviral therapies and treatment optimization strategies.
- SARS-CoV-2 infections
- Antiviral combination therapies
- Herpes Simplex Virus infections
Explores innovative approaches for resistant viral strains, particularly in immunocompromised patients.
Bacterial Infections
Focuses on treating complex bacterial infections including Mycobacterium tuberculosis and Staphylococcus aureus infections. Specializes in catheter-related bloodstream infections.
- Tuberculosis treatment
- Catheter-related infections
- Community-acquired pneumonia
Evaluates innovative antibiotic treatment strategies and duration optimization protocols.
Antimicrobial Therapeutics
Studies advanced treatments for resistant infections and develops customized therapeutic approaches for various infectious diseases. Investigates novel antimicrobial agents.
- Antibiotic resistance management
- Treatment duration optimization
- Clostridioides difficile infection
Implements personalized treatment strategies based on patient-specific factors and pathogen characteristics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.